Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302274 · ClinicalTrials.gov registry record
Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 209
- Enrollment target
NCT02302274 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 209 participants.
The verdict
NCT02302274 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 209 participants
- Enrollment target
Study Summary
The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients and its higher sensitivity when compared to procainamide infusion (the conventional drug used in the USA). As a substudy it proposes to apply this test to early ARVC cases in order to evaluate if ECG changes similar to those seen in Brugada Syndrome could be unmasked by flecainide iv.
Interventions
- DRUG flecainide iv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2010-07-01 |
| Est. Completion | 2017-07-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02302274
The ClinicalTrials.gov registry entry for NCT02302274 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which flecainide iv is the first listed.
NCT02302274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02302274 about?
NCT02302274 is a clinical study titled "Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome". The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients and its higher sensitivity when compared to procainamide infusion (the conventional drug used in the USA). As a substudy ...
What is the current status of trial NCT02302274?
This trial is currently completed. The enrollment target is 209 participants. The study started on 2010-07-01. Estimated completion is 2017-07-26.
What interventions are being tested in trial NCT02302274?
The interventions under investigation include: flecainide iv (DRUG).
Who is sponsoring clinical trial NCT02302274?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.